Tags

Type your tag names separated by a space and hit enter

Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.
Korean J Ophthalmol. 2017 Jun; 31(3):209-216.KJ

Abstract

PURPOSE

To assess the effectiveness and safety of intravitreal ranibizumab compared with bevacizumab for the treatment of macular edema associated with branch retinal vein occlusion (BRVO).

METHODS

This was a retrospective study of 80 eyes with macular edema associated with BRVO. Patients received either 0.5 mg of ranibizumab (n = 24) or 1.25 mg of bevacizumab (n = 56) intravitreally. Both groups received three initial monthly injections followed by as-needed injections. The best-corrected visual acuity, central subfield thickness, mean number of injections, and retreatment rate were evaluated monthly for 6 months after the initial injection.

RESULTS

The best-corrected visual acuity significantly improved from logarithm of the minimal angle of resolution (logMAR) 0.55 ± 0.26 at baseline to 0.24 ± 0.26 at 6 months in the ranibizumab group (p < 0.001) and from logMAR 0.58 ± 0.21 at baseline to 0.29 ± 0.25 at 6 months in the bevacizumab group (p < 0.001), which is not a statistically significant difference (p = 0.770). The mean reduction in central subfield thickness at 6 months was 236 ± 164 μm in the ranibizumab group (p < 0.001) and 219 ± 161 μm in the bevacizumab group (p < 0.001), which is not also a statistically significant difference (p = 0.698). The mean numbers of ranibizumab and bevacizumab injections were 3.25 ± 0.53 and 3.30 ± 0.53, respectively (p = 0.602). In addition, after the three initial monthly injections, the retreatment rates for ranibizumab and bevacizumab injections were 20.8% and 26.7%, respectively (p = 0.573).

CONCLUSIONS

Both ranibizumab and bevacizumab were effective for the treatment of BRVO and produced similar visual and anatomic outcomes. In addition, the mean number of injections and the retreatment rates were not significantly different between the groups.

Authors+Show Affiliations

Department of Ophthalmology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Korea.Department of Ophthalmology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Korea. hwkwak@khu.ac.kr.Department of Ophthalmology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Korea.Department of Ophthalmology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Korea.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

28471106

Citation

Son, Bo Kwon, et al. "Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated With Branch Retinal Vein Occlusion." Korean Journal of Ophthalmology : KJO, vol. 31, no. 3, 2017, pp. 209-216.
Son BK, Kwak HW, Kim ES, et al. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion. Korean J Ophthalmol. 2017;31(3):209-216.
Son, B. K., Kwak, H. W., Kim, E. S., & Yu, S. Y. (2017). Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion. Korean Journal of Ophthalmology : KJO, 31(3), 209-216. https://doi.org/10.3341/kjo.2015.0158
Son BK, et al. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated With Branch Retinal Vein Occlusion. Korean J Ophthalmol. 2017;31(3):209-216. PubMed PMID: 28471106.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion. AU - Son,Bo Kwon, AU - Kwak,Hyung Woo, AU - Kim,Eung Suk, AU - Yu,Seung Young, Y1 - 2017/04/24/ PY - 2015/11/10/received PY - 2016/03/21/accepted PY - 2017/5/5/pubmed PY - 2017/10/13/medline PY - 2017/5/5/entrez KW - Bevacizumab KW - Branch retinal vein occlusion KW - Macular edema KW - Ranibizumab SP - 209 EP - 216 JF - Korean journal of ophthalmology : KJO JO - Korean J Ophthalmol VL - 31 IS - 3 N2 - PURPOSE: To assess the effectiveness and safety of intravitreal ranibizumab compared with bevacizumab for the treatment of macular edema associated with branch retinal vein occlusion (BRVO). METHODS: This was a retrospective study of 80 eyes with macular edema associated with BRVO. Patients received either 0.5 mg of ranibizumab (n = 24) or 1.25 mg of bevacizumab (n = 56) intravitreally. Both groups received three initial monthly injections followed by as-needed injections. The best-corrected visual acuity, central subfield thickness, mean number of injections, and retreatment rate were evaluated monthly for 6 months after the initial injection. RESULTS: The best-corrected visual acuity significantly improved from logarithm of the minimal angle of resolution (logMAR) 0.55 ± 0.26 at baseline to 0.24 ± 0.26 at 6 months in the ranibizumab group (p < 0.001) and from logMAR 0.58 ± 0.21 at baseline to 0.29 ± 0.25 at 6 months in the bevacizumab group (p < 0.001), which is not a statistically significant difference (p = 0.770). The mean reduction in central subfield thickness at 6 months was 236 ± 164 μm in the ranibizumab group (p < 0.001) and 219 ± 161 μm in the bevacizumab group (p < 0.001), which is not also a statistically significant difference (p = 0.698). The mean numbers of ranibizumab and bevacizumab injections were 3.25 ± 0.53 and 3.30 ± 0.53, respectively (p = 0.602). In addition, after the three initial monthly injections, the retreatment rates for ranibizumab and bevacizumab injections were 20.8% and 26.7%, respectively (p = 0.573). CONCLUSIONS: Both ranibizumab and bevacizumab were effective for the treatment of BRVO and produced similar visual and anatomic outcomes. In addition, the mean number of injections and the retreatment rates were not significantly different between the groups. SN - 2092-9382 UR - https://www.unboundmedicine.com/medline/citation/28471106/Comparison_of_Ranibizumab_and_Bevacizumab_for_Macular_Edema_Associated_with_Branch_Retinal_Vein_Occlusion_ L2 - https://ekjo.org/DOIx.php?id=10.3341/kjo.2015.0158 DB - PRIME DP - Unbound Medicine ER -